<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="458">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155189</url>
  </required_header>
  <id_info>
    <org_study_id>0921-028</org_study_id>
    <nct_id>NCT05155189</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>A Clinical Study to Evaluate Safety and Efficacy of C-CAR031 Armored CAR-T Cell Injection in Treatment of Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in&#xD;
      unresectable HCC patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plans to enroll 4-20 patients to assess the safety of C-CAR031. Subjects who meet&#xD;
      the eligibility criteria will receive a single dose of C-CAR031 injection, and will be&#xD;
      followed up post treatment for safety monitoring. The follow up period will last 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TEAEs</measure>
    <time_frame>start pretreatment to 12 months</time_frame>
    <description>treatment emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AESIs</measure>
    <time_frame>start pretreatment to 12 months</time_frame>
    <description>adverse events of special interest</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>C-CAR031</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous C-CAR031 administered by intravenous (IV) infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TC-CAR031</intervention_name>
    <description>Targeting GPC3 armored CART cell injection (C-CAR031)</description>
    <arm_group_label>C-CAR031</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Voluntary participation and able to sign the informed consent form&#xD;
&#xD;
          -  2. Aged 18 to 70 years at screening&#xD;
&#xD;
          -  3. Patients with histologically confirmed hepatocellular carcinoma (HCC) who meet the&#xD;
             following requirements: a. Barcelona Clinic Liver Cancer Stage B or C (BCLC B/C) b.&#xD;
             Child-Pugh score ≤ 6 c. Positive cell membrane GPC3 expression in at least 35% of&#xD;
             tumor cells&#xD;
&#xD;
          -  4. Patients with relapsed / progressive disease after at least one prior standard&#xD;
             systemic therapies for HCC, or ineligible to accept/unable to tolerate the systemic&#xD;
             therapies. Standard systemic therapies may include targeted drugs (such as Sorafenib,&#xD;
             Lenvatinib, Donafenib, Apatinib), immune checkpoint inhibitors (such as Atezolizumab,&#xD;
             Pembrolizumab, Camrelizumab, Sintilimab, Nivolumab, Toripalimab, Tislelizumab) or&#xD;
             chemotherapeutic drugs (such as Oxaliplatin and 5-fu)&#xD;
&#xD;
          -  5. At least one measurable target lesion (as per RECIST v1.1)&#xD;
&#xD;
          -  6. WHO/ECOG performance status (PS) score of 0 or 1 point&#xD;
&#xD;
          -  7. Expected survival ≥ 12 weeks&#xD;
&#xD;
          -  8. Left ventricular ejection fraction (LVEF) by echocardiography ≥ 45%&#xD;
&#xD;
          -  9. No active infection in the lungs&#xD;
&#xD;
          -  10. Laboratory tests: a. Absolute neutrophil count (ANC) ≥ 1.0 × 109/L b. Lymphocyte&#xD;
             count ≥ 0.4 × 109/L c. Platelet count ≥ 60 × 109/L d. Hemoglobin ≥ 80 g/L e. Total&#xD;
             bilirubin (TBIL) ≤ 2 × upper limit of normal (ULN) f. AST and ALT ≤ 5 × ULN g. Serum&#xD;
             creatinine ≤ 1.5 × ULN h. Prothrombin time (PT): prolonged PT ≤ 4 s&#xD;
&#xD;
          -  11. Patients without history of HBV infection, or with HBV DNA &lt; 500 IU/mL (or 2500&#xD;
             copies/mL) at screening who agree to receive anti-virus therapies throughout the study&#xD;
             according to the guidelines&#xD;
&#xD;
          -  12. Negative serum or urine pregnancy test results for females of child-bearing age at&#xD;
             screening; In addition, they should agree to take effective contraceptive measures&#xD;
             throughout the study&#xD;
&#xD;
          -  13. Patients who agree to abstain from drinking throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of severe allergies or allergic to the excipient DMSO of the cell product&#xD;
&#xD;
          -  2. History of liver transplantation&#xD;
&#xD;
          -  3. History of prior cell therapy&#xD;
&#xD;
          -  4. Tumor volume &gt; 70% of the liver&#xD;
&#xD;
          -  5. portal stem vein tumor thrombus&#xD;
&#xD;
          -  7. Metastases to bones or central nervous system (CNS), or involved CNS&#xD;
             diseasesincluding hepatic encephalopathy, epilepsy, cerebrovascular accidents, etc.&#xD;
&#xD;
          -  8. Receipt of radiotherapy within 6 weeks prior to apheresis&#xD;
&#xD;
          -  9. Receipt of Local therapy (such as surgery, ablation, and intervention) within 4&#xD;
             weeks prior to apheresis or presence of unhealed wounds before apheresis 10. Receipt&#xD;
             of systemic treatment and failure to meet the minimum requirements for wash-out&#xD;
             periods before apheresis: a. Immune checkpoint inhibitors: 6 weeks b. Systemic&#xD;
             anti-tumor therapies using experimental anticancer drugs or other Chinese herbal&#xD;
             medicines and Chinese patent medicines with unclear mechanisms:2 weeks c. Steroids&#xD;
             (except inhaled steroids) or other immunomodulators (including interleukins,&#xD;
             interferons, and thymosins) of systemic therapeutic dose: 2 weeks&#xD;
&#xD;
          -  11. Other history of primary cancers, excluding:a. Nonmelanoma skin cancer cured by&#xD;
             resection (such as basal cell carcinoma) b. Cured carcinoma in situ (such as cervical&#xD;
             cancer, bladder cancer, and breast cancer)&#xD;
&#xD;
          -  12. Active hepatitis C virus infection (HCV RNA positive)&#xD;
&#xD;
          -  13. Syphilis infection&#xD;
&#xD;
          -  14. History of active/immunodeficient diseases (including but not limited to HIV,&#xD;
             systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis,&#xD;
             myasthenia gravis, Graves' disease, and hypophysitis; excluding: vitiligo or alopecia,&#xD;
             hypothyroidism in patients with stable medical conditions after hormone replacement&#xD;
             therapy, any chronic skin conditions that need no systemic treatment, and other&#xD;
             diseases judged by the investigator to be of no clinical significance)&#xD;
&#xD;
          -  15. Persistent and active infections (excluding prophylactic anti-infectives)&#xD;
&#xD;
          -  16. Uncontrolled hypertension, diabetes, arrhythmia, and symptomatic congestive heart&#xD;
             failure&#xD;
&#xD;
          -  17. Dementia or mental state changes supported by obvious clinical evidence&#xD;
&#xD;
          -  18. Cardiac insufficiency: class III or IV, according to the New York Heart&#xD;
             Association (NYHA) functional classifications&#xD;
&#xD;
          -  19. Unstable heart or lung diseases&#xD;
&#xD;
          -  20. Obvious bleeding risks or tendencies&#xD;
&#xD;
          -  21. Females who are pregnant or breastfeeding or expect to be pregnant or&#xD;
             breastfeeding during the study&#xD;
&#xD;
          -  22. Other diseases that may add further risks to the subject or interfere with the&#xD;
             study results as judged by the investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qihan Fu</last_name>
    <phone>18268173309</phone>
    <email>ayfuqihan@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China，310000</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 7, 2021</study_first_submitted>
  <study_first_submitted_qc>December 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>TingBo Liang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

